Table 4:
No. | Item Description | Lee et al.9 | Soylu et al.10 | Fu et al.11 | Chang et al.12 | Vithoulka et al.13 | Slupik et al.14 | Aktas et al.15 | Yoshida et al.16 | Huang et al.17 | Lee et al.18 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Randomized | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 2 |
2 | Baseline Characteristics | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 |
3 | Prognostic Stratification | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
4 | Blinding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
5 | Method Protocol | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
6 | Compliance | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
7 | Follow-up | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
8 | Sources of Error | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
9 | Statistical Significance | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
10 | Clinical Significance | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Total Score | 16/20 | 15/20 | 17/20 | 17/20 | 16/20 | 14/20 | 16/20 | 17/20 | 16/20 | 16/20 |